Advances in Research on Lipid-Lowering Mechanisms of Eight Medicinal Plants

被引:0
|
作者
Yang, Huangqizi [1 ]
机构
[1] Jiangxi Univ Tradit Chinese Med, Sch Pharm, Nanchang 330004, Jiangxi, Peoples R China
关键词
Hyperlipidemia; Herbs; Lipid-Lowering Active Ingredients; Lipid-Lowering Mechanisms; INDUCED OXIDATIVE STRESS; INSULIN-RESISTANCE; BETA-CELL; GREEN TEA; HIGH-FAT; INTESTINAL-ABSORPTION; CISSAMPELOS-PAREIRA; ZINGIBER-OFFICINALE; ETHANOLIC EXTRACT; LEAF EXTRACT;
D O I
10.1063/1.5085520
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Hyperlipidemia is a disease of fat metabolism or abnormal operation in healthcare, characterized by one or more of high total cholesterol (TC), high triglycerides (TG), high low-density lipoprotein cholesterol (LDL-C) and low high-density lipoprotein cholesterol (HDL-C) in blood. Hyperlipidemia is prone to cardiovascular and cerebrovascular diseases, obesity, diabetes, hyperinsulinemia and other diseases, posing a serious threat to human health. However, the commonly used chemical synthetic lipid-lowering drugs have obvious clinical effects, but the effect is biased to single and adverse reactions, such as adverse reactions of the nervous system, gastrointestinal reactions and liver damage. In recent years, a large number of literatures had reported that various medicinal plants or their active ingredients had lipid-lowering effects. Thus, finding safe and effective lipid-lowering components from natural medicines has a broad development prospects in research. In this review, I tried to explore the information of several active components of lipid-lowering plants and their lipid-lowering mechanisms, which may help future researchers develop new natural lipid-lowering drugs to treat hyperlipidemia.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Clinician Decision Support Tools: Advances in Lipid-Lowering Treatment Intensification
    Marvel, Francoise A.
    Grant, Jelani K.
    Martin, Seth S.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2024, 17 (05):
  • [32] Advances in lipid-lowering therapy through gene-silencing technologies
    Børge G. Nordestgaard
    Stephen J. Nicholls
    Anne Langsted
    Kausik K. Ray
    Anne Tybjærg-Hansen
    Nature Reviews Cardiology, 2018, 15 : 261 - 272
  • [33] Lipid-lowering drugs and homocysteine - A comparison between statins and other lipid-lowering drugs
    Jankowski, P
    Kawecka-Jaszcz, K
    ATHEROSCLEROSIS, 2004, 172 (01) : 191 - 194
  • [34] LIPID-LOWERING DIETARY ADVICE
    ANGELICO, F
    VOLPE, R
    BRITISH MEDICAL JOURNAL, 1995, 310 (6995): : 1669 - 1669
  • [35] LIPID-LOWERING THERAPY IN PERSPECTIVE
    THOMPSON, GR
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1988, 42 (02): : 61 - 64
  • [36] LIPID-LOWERING EFFECTS OF PROCETOFENE
    AFSCHRIFT, M
    METS, T
    VERDONK, G
    LANCET, 1977, 2 (8032): : 311 - 311
  • [37] Pharmacoeconomics of lipid-lowering drugs
    Dean G. Smith
    Current Atherosclerosis Reports, 2003, 5 (1) : 67 - 72
  • [38] Lipid-lowering therapies in development
    Wierzbicki, AS
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (11) : 1405 - 1418
  • [39] Lipid-lowering Therapies in Myositis
    Marisa C. Mizus
    Eleni Tiniakou
    Current Rheumatology Reports, 2020, 22
  • [40] Choice of lipid-lowering drugs
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1998, 40 (1042): : 117 - 122